Matritech raises $6.56 million to step up IVD (in vitro diagnostic) work:
This article was originally published in Clinica
Matritech, of Newton, Massachusetts, has sold common stock and warrants in a private placement that raised $6.56m, or $5.85m net. The diagnostic proteomics company says the funds will be used to increase marketing and sales efforts, as well as for ongoing in vitro diagnostic development, clinical trials, working capital, capital expenditures and general corporate purposes. Matritech has two approved products for diagnosing and monitoring bladder cancer, and has discovered proteins associated with cervical, prostate, breast and colon cancer.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.